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Abstract
Background: Sulphadoxine-pyrimethamine (SP) resistance is now widespread throughout east and southern Africa
and artemisinin compounds in combination with synthetic drugs (ACT) are recommended as replacement
treatments by the World Health Organization (WHO). As well as high cure rates, ACT has been shown to slow the
development of resistance to the partner drug in areas of low to moderate transmission. This study looked for
evidence of protection of the partner drug in a high transmission African context. The evaluation was part of large
combination therapy pilot implementation programme in Tanzania, the Interdisciplinary Monitoring Programme for
Antimalarial Combination Therapy (IMPACT-TZ)
Methods: The growth of resistant dhfr in a parasite population where SP Monotherapy was the first-line treatment
was measured for four years (2002-2006), and compared with the development of resistant dhfr in a neighbouring
population where SP + artesunate (SP+AS) was used as the first-line treatment during the same interval. The effect
of the differing treatment regimes on the emergence of resistance was addressed in three ways. First, by looking
at the rate of increase in frequency of pre-existing mutant dhfr alleles under monotherapy and combination
therapy. Second, by examining whether de-novo mutant alleles emerged under either treatment. Finally, by
measuring diversity at three dhfr flanking microsatellite loci upstream of the dhfr gene.
Results: The reduction in SP selection pressure resulting from the adoption of ACT slowed the rate of increase in
the frequency of the triple mutant resistant dhfr allele. Comparing between the two populations, the higher levels
of genetic diversity in sequence flanking the dhfr triple mutant allele in the population where the ACT regimen
had been used indicates the reduction in SP selection pressure arising from combination therapy.
Conclusion: The study demonstrated that, alleles containing two mutations at the dhfr have arisen at least four
times independently while those containing triple mutant dhfr arose only once, and were found carrying a single
unique Asian-type flanking sequence, which apparently drives the spread of pyrimethamine resistance associated
dhfr alleles in east Africa. SP+AS is not recommended for use in areas where SP cure rates are less than 80% but
this study reports an observed principle of combination protection from an area where pyrimethamine resistance
was already high.
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Artemisinin-based combination therapy (ACT) is the
World Health Organization (WHO) recommended anti-
malarial in areas where SP failure prompts replacement.
Already, Tanzania has replaced SP with a combination
of artemether and lumefantrine (Coartem
®). However,
SP remains the only option for intermittent treatment of
malaria during pregnancy and an important drug in the
intermittent treatment of infant. Therefore, priority
remains for continuing surveillance and monitoring of
genetic changes of SP resistance in the population.
SP kills parasites by inhibiting folate biosynthetic path-
way [1-3]. Pyrimethamine competitively inhibits the
enzyme dihydrofolate reductase, DHFR [1] while sulpha-
doxine does the same to inhibit the enzyme dihydropteo-
rate synthase, DHPS [2,3]. Resistance to SP is associated
with point mutations in the genes coding for the two
enzymes, dhfr and dhps [4-8]. Single mutation at codon
108 (S108T) confer low level of insensitivity to the drug
[5]. Additional mutations increases the insensitivity of the
parasite to the drug; the double mutation (N51I+S108N)
or (C59R+S108N) confers intermediate resistance [5,9]
increasing to triple mutations (N51I+C59R+S108N). An
additional mutation at codon 164 (I164L) leading to quad-
ruple mutant, cause highest level of resistance to SP. It is
now known that, quadruple mutation exist in Africa in a
very low frequency [10-13, this study], although recent
study in Uganda [14] indicates its frequency is increasing.
There is currently conflicting information about how SP
resistant alleles originate and spread across populations
[13-20]. Early studies suggest that, the dhfr triple mutant
allele is monophyletic in origin indicating it has arisen
once [15] and subsequent studies reported the lineage had
arisen in south-east Asia [16]. Although many studies that
followed confirmed this observation [14,17-20], a study in
an area of high malaria transmission in western Kenya
identified presence of multiple lineages of the dhfr triple
mutant allele [13], and concluded that, local evolutionary
history as well as dispersal by gene flow are equally impor-
tant in the establishment of resistance in populations.
This study has investigated the rate of selection and
evolution of dhfr resistant alleles in two populations
with contrasting anti-malarial therapies, Kilombero-
Ulanga under SP monotherapy and Rufiji under SP+AS.
By using three sets of microsatellite loci flanking the
dhfr gene, the study investigated the evolutionary origin
of resistant dhfr alleles and compares the rate of under-
lying genetic exchange between the two populations.
Methods
Study area, subjects and samples
Samples were collected through three community cross
sectional surveys conducted during July-September in
2001, 2002 and 2006 in three rural districts of south-
eastern Tanzania; Rufiji (Population = 203,000), Kilo-
mbero (Popupulation. = 322,000) and Ulanga (Popula-
tion = 194,000). The surveys were part of large
combination therapy pilot implementation programme
in Tanzania, the Interdisciplinary Monitoring Pro-
gramme for Antimalarial Combination Therapy
(IMPACT-TZ). IMPACT-Tanzania is a multiyear imple-
mentation research evaluation that rests on a collabora-
tive platform incorporating the US Center for Disease
Control and Prevention (CDC), the Ifakara Health Insti-
tute (IHI), London School of Hygiene and Tropical
Medicine (LSHTM), and the Ministry of Health and
Social Welfare including its National Malaria Control
Programme, the Tanzania Essential Health Interventions
Project and the Council Health Management Teams of
Rufiji, Kilombero, Ulanga, Morogoro and Mvomero Dis-
tricts. For the purpose of the study, Kilombero and
Ulanga Districts were treated as a single district because
population movement between these two districts is
high and the study population spans the border region.
Plasmodium falciparum malaria transmission in the
study area was intense (with an estimated entomological
inoculation rate of 367 infectious bites per person per
year [21] and perennial with some seasonal fluctuation
(however, recent studies indicate decrease in malaria
transmission in all endemic areas but new entomological
inoculation rate for the studied area has not yet been re-
determined). The survey conducted in Jul-Sept 2001
coincided with the implementation of new national pol-
icy replacing CQ with SP as the recommended first-line
treatment of uncomplicated malaria. In 2002 the timing
of the survey coincided with the implementation of SP
+AS combination in Rufiji. While the national policy
change to SP in 2001 was implemented nationwide, the
change from SP to SP+AS combination in 2002 was
applied in Rufiji district only.
A total of 22,696 adults and children belonging to ran-
domly selected households participated in the study
(6,482, 7,447 and 8,767 in 2001, 2002 and 2006 survey,
respectively), and a finger-prick blood sample for blood
slide and filter paper bloodspot were collected from
each individual. The filter paper bloodspots were air-
dried and stored at room temperature in self-sealing
plastic bags with desiccant and stored at room tempera-
ture for future use in genetic testing. All blood slide
s a m p l e sw e r es c r e e n e db ym i c r o s c o p yf o rP. falciparum
positivity. Bloodspots from microscopically positive sub-
jects were selected for molecular genotyping.
Ethics
Scientific and ethical clearance was granted from the
Medical Research Council of the National Institute for
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Control and Prevention, USA, and the London School
of Hygiene and Tropical Medicine, UK. Consent was
obtained from all individuals or their guardians before
collection of samples.
DNA extraction
The DNA was extracted from bloodspots dried on filter
papers. A sector of the dried blood spot filter paper was
excised using a sterile blade or scissors, and soaked in a
1 ml, 0.5% saponin-1x phosphate buffered saline (PBS)
overnight in a 96-deepwell plate. The segment was then
washed twice in 1 ml of 1x PBS and finally, was boiled
for 8 min in 100 ul PCR quality water with 50 ul 20%
chelex suspension (pH 9.5).
PCR amplification
Nested PCR was used to amplify a 594 bp fragment of
dhfr containing the sequence where mutations are
found. Primer sequences and PCR reaction conditions
were previously described in [22] PCR was performed in
96 well plates with 25-μl PCR reaction volumes contain-
ing final concentrations of 0.25 μM oligonucleotide pri-
mers, 2 mM MgCl2,2 5 0μM each deoxyribonucleotide
triphosphate (dNTPs), and 1x Taq polymerase. One
microlitre (1 μl) of DNA template was used in the outer
(primary) PCR reaction mixture. The outer dhfr PCR
products were diluted three fold before a 1 ul was intro-
duced into the inner PCR reaction mixtures.
Molecular genotyping of point mutations by Sequence
Specific Oligonucleotide Probing (SSOP)
The amplified PCR products were screened for dhfr
sequence variants at 5 loci where single nucleotide poly-
morphisms (SNPs) are known. The sequence changes
(and the amino acid substitutions they code for) are
summarized in Table 1.
PCR products were spotted in a 12 by 8-grid and
cross linked onto nylon membranes and probed for
sequence polymorphisms by hybridisation to specific oli-
gonucleotide probes described previously [21]. The
probed blots were visualized using ECF substrate and
detection using a phosphorimager (STORM). Inspection
of the phophorimager output was recorded through
viewing of digitally captured images of chemi-fluores-
cent signal.
The stringency and specificity of the hybridisation
process was confirmed by inspection of a series of four
controls of known single genotype variant sequence. All
blots with non-specifically bound probes were stripped
and re-probed. A SNP was considered to be present in
the PCR product when the intensity of signal was higher
than that of the background. The blots were scored
independently by two people and the results reconciled.
The study aimed to establish the relative abundance of
different point mutation haplotypes at dhfr. Since blood-
stage P. falciparum is haploid this is very straightfor-
ward when an infection consists of a single genotype
because only one form of sequence is seen at every SNP
locus. When infections are composed of multiple geno-
types a mixture of different sequence variants occur
making the inference of point mutation haplotypes
within that infection impossible.
The presence, absence, and relative abundance of
hybridisation signal were recorded for every probe at
each locus. A sample was considered to have a single
haplotype when only one sequence variant was found at
each locus. Blood samples were categorized as having a
single, a majority or mixed form of sequence at every
SNP locus. Majority and mixed genotype infections were
differentiated according to the relative intensity of sig-
nal. To determine the relative abundance of different
point mutation haplotypes in the parasite population
one haplotype only was counted from each infection
and those mixed infections where haplotypes could not
be resolved were omitted from the calculation of haplo-
type frequencies. Hence frequency data is based upon a
subset of isolates, which were unmixed or had a predo-
minating majority haplotype. A breakdown of the pro-
portions of isolates which PCR amplified and which
were genotyped as single, majority or mixed haplotype
infections obtained for the 2006 annual survey is given
in Table 2.
Microsatellite analysis
In order to analyse microsatellite immediately flanking
sequence polymorphism on chromosomes carrying spe-
cific allelic forms of dhfr, the study used the genotype
Table 1 The nucleotide and amino acid substitutions at dhfr gene screened for by PCR-SSOP
Codon 50 51 59 108 164
Wild type Cys (C)
TGT
Asn (N)
AAT
AAC
Cys (C)
TGT
Ser (S) AGC Ile (I)
ATA
Mutant Arg (R)
CGT
Ile (I)
ATT
Arg (R)
CGT
Asn (N) AAC
Thr (T)
ACC
Leu (L)
TTA
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identify and locate DNA sample bearing that particular
allelic form. For the purpose of looking on these flank-
ing sequence polymorphisms, the study deliberately
selected a subset of samples that were unmixed at any
polymorphic loci at dhfr (i. e. samples in which only sin-
gle haplotype were obtained). Nonetheless, two or more
alleles were still detected in some of the samples and
such samples were classified as polyclonal and hence
were excluded from haplotype construction and any
further analysis. Microsatellite sequence located 0.3 kb,
4.4 kb, and 5.3 kb upstream of codon 108 of the dhfr-ts
gene, which is on chromosome 4, were analysed. A semi
nested PCR system employing the primer sequences and
PCR cycling parameters described in [15] was used. A
total of 728 samples comprising of 126 dhfr wild type
(N51+C59+S108), 346 double mutant dhfr (N51I
+S108N or C59R+ S108N) and 256 triple mutant dhfr
(N51I+ C59R+ S108N) were selected from 2001, 2002
and 2006 genotypic data. Microsatellite PCR samples
were diluted 1:100 and run with LIZ-500 size standard
on an ABi 3730 genetic analyser (Applied Biosystems,
Warrington, Cheshire, UK). Allelic sizes were separated
on an Applied Biosystems ABi 3730 capillary sequencer
and were scored using Gene Mapper software version
3.7 (Applied Biosystems, Warrington, Cheshire, UK).
Statistical analysis
Statistical comparison of allele frequencies at dhfr was
carried out using Fishers exact test in STATA version
9.2. The calculation of binomial exact 95% confidence
intervals was carried out using STATA version 9.2 [23].
Gene diversity values was calculated as He = [n/(n-1)]
[1- ΣPi
2] where n is the number of samples and Pi is
the frequency of the ith allele.
Results
Of 22,696 people sampled, 4,778 were found to be
infected with P. falciparum.D N Aw a se x t r a c t e df r o m
the 4,778 P. falciparum positive bloodspots and PCR
amplification of dhfr performed once, giving a combined
rate of PCR amplification success of 74% (Table 2). The
amplified products were screened for all the variant
sequences described in Table 1. Out of the 3,521 isolates
which amplified successfully for dhfr, 2,565 (80%) were
single or majority genotype infections and the point
mutation haplotypes could easily be resolved.
Point mutations were detected at codons 51, 59, 108
and 164 of the dhfr gene. The same mutations with the
exception of codon 164 was reported in previous studies
in Tanzania [15,22,24,25] and are common throughout
east Africa, Malawi [26], Kenya [27,28] and Uganda
[29,30]. These point mutation occurred in four haploty-
pic configurations at dhfr (sensitive, N51+C59+S108,
double mutant, N51I+S108N or C59R+S108N, and triple
mutant, N51I+C59R+S108N). Rare haplotypes were also
detected at dhfr gene (single mutants, S108N and C59R)
in each case the frequency of the haplotype was < 4%.
Mutation at codon 164 (I164L) was detected in only one
of the 3,521 isolates that amplified at dhfr gene, and it
occurred as a mix of minority mutant in a sensitive
majority. Figure 1 compares change in frequency of alle-
lic haplotypes at dhfr over time, in Rufiji (implementing
SP + AS combination, Figure 1a) and Kilombero-Ulanga
(implementing SP monotherapy, Figure 1b).
A similar trend of the dhfr allelic frequency change
over time was observed both in Kilombero-Ulanga and
Rufiji populations, indicating that ACT in Rufiji had lit-
tle and non significant effect on the increase of resistant
dhfr alleles. Most striking is the effect of national policy
change from CQ to SP first-line treatment in late 2001,
leading to significant rapid increase of triple mutant
dhfr allele in both districts (P ≤ 0.0001), displacing the
sensitive dhfr allele as described in detail elsewhere [25].
Changes in the frequency of the dhfr triple mutant allele
(N51I+C59R+S108N) are shown in Figure 2. Its fre-
quency was significantly higher in Rufiji than in Kilo-
mbero-Ulanga between 2001 and 2002, yet the increase
of this allele during 2001- 2002 period was highly signif-
icant in both Kilombero-Ulanga (p ≤ 0.0001) and Rufiji
(p ≤ 0.0001). Although at the start of SP+AS combina-
tion in Rufiji in late 2002 the frequency of triple mutant
dhfr allele was higher in Rufiji (63%) than Kilombero-
Ulanga (52%), the ACT slowed its rate of increase in
R u f i j iw h e r eb y2 0 0 6t h ef r e q u e n c yw a sh i g h e ri nK i l o -
mbero-Ulanga (75%) than Rufiji (74%).
In 2001, the frequency of the sensitive dhfr haplotype
(N51+C59+S108) was significantly higher in Kilombero-
Table 2 Proportion of samples that were P.falciparum positive, PCR amplified dhfr, and single/majority dhfr
Year Rufiji Kilombero Ulanga
2001 2002 2006 2001 2002 2006
Survey population 3285 3349 4267 3197 4098 4500
P. falciparum positive 908 (27.6%) 854 (25.5%) 916
(21.5%)
580
(18.1%)
875
(21.3%)
645
(14.3%)
PCR amplified dhfr 683 687 683 488 686 294
Single or majority dhfr 420 527 616 238 489 275
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ple mutant dhfr allele increased in both districts, the
sensitive dhfr allele was displaced proportionately redu-
cing its frequency to (6%) in Kilombero-Uanga and (4%)
in Rufiji (P ≥ 0.05) by 2006. The N51I+S108N and
C59R+S108N double mutant dhfr alleles persisted
throughout unchanged with an average frequency of
roughly 10% at both populations, indicating they are
independent of drug pressure (Figure 1).
T h ee v o l u t i o n a r yo r i g i n so fdhfr haplotypes was
assessed by genotyping 728 isolates (CNCS = 126,
CNRN + CICN = 346, and CIRN = 256) of P. falci-
parum carrying resistant or the sensitive dhfr alleles.
Although all these samples were unmixed based on the
PCR-SSOP point mutation genotype data, 99 (14%)
   (a) 
 
   (b) 
Figure 1 Allelic haplotype frequency change at dhfr gene over time: (a) Rufiji (b) Kilombero - Ulanga. Frequency values are shown with
95% CI bars calculated by binomial exact method.
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Figure 2 Comparison of dhfr triple mutant allelic haplotype
between Kilombero-Ulanga and Rufiji populations in 2001,
2002 and 2006. Frequency values are shown with 95% CI bars
calculated by binomial exact method.
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Page 5 of 13isolates contained > 1 allele at one or more microsatel-
lite loci, indicating existence of multiple P. falciparum
clones while also highlighting higher sensitivity of
microsatellite in detecting polyclonality compared to
PCR-SSOP method. A further 183 (25%) isolates did not
amplify at one or more microsatellite loci making con-
struction of haplotype incomplete. Both the polyclonal,
and isolates with incomplete microsatellite data were
excluded from haplotype construction and any further
analysis. Overall, 446 (61%) isolates, were included in
haplotype construction and analysis of diversity values;
78 were the dhfr sensitive, 184 double mutant dhfr
(C59R + S108N or N51I + S108N) and 184 the triple
mutant dhfr (N51I + C59R + S108N).
Polymorphisms at microsatellite loci were recorded
(Table 3). Numerous alleles at the 3 dhfr linked micro-
satellite loci were identified. The -0.3 kb locus had 11
alleles of 85-115 bp, the -4.4 kb locus had 19 alleles of
156-199 bp and the -5.3 kb locus had 18 alleles of 190-
221 bp, and these were evenly distributed among the
two named districts.
Frequency of microsatellite alleles flanking the sensi-
tive and triple-mutant dhfr allele groups are presented
in Figure 3. In the sensitive type dhfr, many alleles were
detected at each microsatellite locus revealing high
diversity in the DNA flanking the sensitive dhfr alleles.
In the dhfr triple-mutant group, at each locus, few low-
frequency alleles and a single predominant allele were
found in most isolates. These alleles were the 108 bp at
-0.3 Kb, 176 bp at -4.4 Kb and the 203 bp at the -5.3
Kb highlighting the extent of lost diversity. The high fre-
quency of allele 108, 176 and 203 reflect the shared
ancestry of the triple mutant in these populations while
the observed rare alleles are reflection of the recent evo-
lution by mutation or recombination [31,32].
Three-locus microsatellite haplotypes were con-
structed from the 446 unmixed isolates, in the sensitive,
double mutant (C59R+S108N), double mutant (N51I
+S108N) and triple mutant dhfr groups (see Additional
file 1). A total of 104 different haplotypes were identi-
fied, ranked and numbered according to size of allele at
-0.3 Kb then at -4.4 Kb and finally at -5.3 Kb locus and
numbered from H1-H104. Of the 104 different
microsatellite haplotypes, 56 were identified among the
78 sensitive isolates, 19 among the 87 C59R+S108N
double mutant isolates, 26 among the 97 N51I+S108N
double mutant isolates and 21 were identified among
the 184 triple mutant dhfr isolates. Nine haplotypes
(H16, H22, H32, H35, H36, H39, H47, H51 and H53)
were shared differently between sensitive and double
mutant and triple mutant dhfr allele (Additional file 1).
Two others (H45 and H52) found among 19 C59R
+S108N double mutant isolates were shared with the
N51I+S108N double mutant dhfr.H 9 0w a si nt h e
majority of the triple mutant dhfr isolates (135 of 184)
but was also found in 2 of 106 among N51I+S108N
double mutant dhfr isolates. H89 was shared (2 of 106
against 2 of 184) among the N51I+S108N double
mutant and the triple mutant dhfr isolates, respectively.
This large extent of haplotype sharing is probably a
reflection of high degree of recombination in this area
of stable high malaria transmission and is consistent
with a similar finding in Kenya [20]. The findings
reported here confirms recent findings from Kilifi Kenya
[20], reporting high levels of microsatelite haplotype
recombination.
There was a clear difference in the haplotypic diversity
between the sensitive and all resistant forms of the dhfr
chromosomes. While the sensitive forms revealed high
diversity with all the 56 haplotypes among 78 isolates
contributing on average equally to the gene pool, the
resistant forms had just a few predominant haplotypes,
with the number of dominant haplotypes decreasing
with increasing level of resistance (Figure 4). The triple
mutant dhfr chromosome had a single dominant haplo-
type (H90) which was identical to the Asian origin type
described in [16], and later reported to be wide-spread
in Africa; Tanzania, Mozambique and South Africa [17],
Senegal [18], Kenya [13,20], Benin, Cameroon, Comoros,
Congo-Brazzaville, Ivory coast, Gabon, Ghana, Guinea,
Mali, Senegal and Uganda [14,19]. Seventy three percent
(135) of the triple mutant dhfr isolates analysed here
were found to carry this haplotype.
Beside the predominant haplotype H90, the triple
mutant dhfr had 21 other microsatellite haplotypes, and
these differed at one or two of the three flanking micro-
satellite loci. These alternative haplotypes were generally
of low frequency of < 2% (except haplotype 21 which
occurred at 11% frequency) and most likely to be rela-
tives of the dominant haplotype with the different
microsatellite allele(s) possibly introduced by recombina-
tion with the double dhfr mutant types. An exception
however, is the existence of four haplotypes (H32, H35,
H18 and H38), which had the 87 bp allele at the closest
dhfr microsatellite loci (-0.3 Kb). The 87 bp allele at -0.3
Kb loci is a common allele for the sensitives and double
dhfr mutants, while 108 bp is for the triple dhfr
Table 3 Number of alleles (A) and allele length range at
the three microsatellite loci in Kilombero-Ulanga and
Rufiji populations
Locus Kilombero-Ulanga Rufiji Overall
A Size range
(bp)
A Size range
(bp)
A Size range
(bp)
-0.3 10 85-115 9 87-115 11 85-115
-4.4 17 158-193 17 156-199 19 156-199
-5.3 15 190-219 13 190-221 18 190-221
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represent cases where double mutants have acquired an
extra mutation transforming to triple dhfr mutant types.
Two novel haplotypes (H29 and H58) associated with
the triple mutant type were identified and differed by
allele length with the dominant (Asian type) haplotype
at all three microsatellite loci. They have not been
described before and in this study each was present in
one isolate only. The haplotypic diversity displayed by
the double mutant dhfr isolates was intermediate
between that found in the sensitive and triple mutant
dhfr types. Both double mutant dhfr alleles were asso-
ciated with four common haplotypes, the C59R+S108N
with H35, H51, H34 and H64 and N51I+S108N with
H22, H32, H39 and H51. H64 was the most common
for the C59R+S108N double mutant, while H51 was the
most common for the N51I+S108N double mutant dhfr.
Both haplotypes were reported in Tanzania and South
Africa [15] and later found in other African P. falci-
parum populations [13,14,17-19].
Both dhfr double mutant alleles heterozygosity values
were almost similar (C59R+S108N; He = 0.800 in 2001/02
and 0.86 in 2006 in Rufiji and 0.85 in 2001/02 and 0.87 in
2006 in Kilombero-Ulanga, and N51I+S108N; He = 0.81
in 2001/02 and 0.78 in 2006 in Rufiji and 0.85 in 2001/02
and 0.79 in 2006 in Kilombero-Ulanga) in both popula-
tions indicating little change in diversity over time (Figure
5). To examine if there were any temporal or geographical
trends in the extent of diversity flanking the major resis-
tance alleles, isolates from two populations of Kilombero-
Ulanga and Rufiji at two time points (2001/02 and 2006)
were compared. Generally, it was observed that the com-
mon microsatellite haplotypes associated with resistant
dhfr chromosomes were broadly consistent at both surveys
(2001/02 and 2006). Distribution of both common haplo-
types and heterozygosity values at two survey points
Figure 3 Frequency and distribution of microsatellite allele at the 3 loci upstream of dhfr gene. Sensitive (white) on the left and Triple
mutant dhfr (black) on the right.
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Page 7 of 13(2001/02 versus 2006) and between the two populations
(Kilombero-Ulanga versus Rufiji) indicated that the two
populations were broadly similar, and this is most likely
attributed to gene flow.
The study also examined the levels of gene diversity,
by computing haplotype-based heterozygosity values for
each dhfr allele (Figure 5). The sensitive dhfr allele had
highest diversity, He of 0.99 and 0.97 in Kilombero-
Ulanga and Rufiji, respectively, reflecting its ancestral
state [15]. By contrast, the resistant dhfr alleles showed
a progressive decrease of diversity with increasing num-
ber of mutation; the dhfr double mutant C59R+S108N,
He = 0.863, 0.8309 and N51I+S108N, He = 0.8262,
0.7978 in Kilombero-Ulanga and Rufiji, respectively.
 
 
 
Figure 4 Microsatellite allele haplotypes in the flanking region upstream of dhfr.
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detected in the triple mutant dhfr indicating more than
a half of heterozygosity had disappeared, He = 0.3419
and 0.4828, in Kilombero-Ulanga and Rufiji, respectively,
when compared with sensitive dhfr alleles. The hetero-
zygosity values for the resistant dhfr alleles between the
2001/02 and 2006 at the two populations of Rufiji and
Kilombero-Ulanga were also compared (Figure 6).
The temporal relationship comparing triple mutant
dhfr allele heterozygosity values between Kilombero-
Ulanga and Rufiji populations generated interesting find-
ings. In Rufiji, He was 0.34 in 2001/02, but increased
slightly to 0.55 in the 2006 while in Kilombero-Ulanga,
He was 0.65 in 2001/02 but decreased dramatically to
0.23 in 2006. These findings indicate that while escala-
tion of SP drug pressure in Kilombero-Ulanga led to
dramatic loss of gene diversity, SP+AS in Rufiji was
associated with halt of the loss and stabilization of gene
diversity of the triple mutant dhfr allele. Both the sensi-
tive and double mutant dhfr alleles did not seem to
respond to either SP or SP+AS drug pressure.
Discussion
The study indicate that the escalation of dhfr triple
mutant resistance allele between 2001/02 - 2006 in
Kilombero-Ulanga and Rufiji populations coincided with
t h ec h a n g eo fN a t i o n l aa n t i - m a l a r i a lp o l i c yf r o mC Q
first line to SP in late 2001/02. In fact, this observation
is concordant to the results of SP treatment efficacy
monitoring in southeast Tanzania during 2003, which
found that 49% of SP treatments failed by day 28 [33]. It
is worth noting that, the observed escalation of dhfr tri-
ple mutant resistance allele in the study districts, was
the continuation of already established pyrimethamine
resistance, following 18 years of SP use as a second-line
treatment since 1983. By the time SP was officially
replacing CQ as national first line treatment for uncom-
plicated malaria, the frequencies of the dhfr triple
mutant resistance allele were 31% and 47% in Kilo-
mbero-Ulanga and Rufiji districts, respectively. As the
SP became widely used between late 2001/02-2006, drug
pressure intensified and the triple mutant dhfr (N51I
+C59R+S108N) allele escalated by a > 2-fold increase in
Kilombero-Ulanga population. In Rufiji population the
SP drug pressure that was initiated by the change of
National anti-malarial guideline in late 2001/02 was
interrupted by introduction of SP+AS combination in
late 2002. It is widely believed that ACT acts so rapidly
killing parasite biomass irrespective of their resistant
properties, potentially reducing the likelihood that resis-
tant parasites spread within the community as well as
 
   
Figure 5 Dhfr flanking microsatellite heterozygosity. A) 2001/02
and B) 2006. Note: in B the CNCS was already too rare to get
sufficient samples.
 
 
Figure 6 Dhfr flanking microsatellite heterozygosity.A )
Kilombero-Ulanga B) Rufiji. Note: in 2006 the CNCS was already too
rare to get sufficient samples.
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[34,35]. While the combination of SP+AS is not recom-
mended for use in areas where SP cure rates are lower
than 80%, the present study indicate that SP+AS combi-
nation slowed the escalation of resistant dhfr alleles rela-
tive to Kilombero-Ulanga, from 11% higher in Rufiji in
2002 to 1% lower in 2006 relative to Kilombero-Ulanga,
even though the SP cure rate was lower than 51% in the
population [33].
While the growth of triple mutant allele in Kilombero-
Ulanga can be explained by the expansion of the triple
mutant dhfr lineage under selection by SP treatment,
the failure of SP+AS combination to halt the increase of
triple mutant dhfr allele frequency in Rufiji requires
some explanations. There are several key ways in which
the application of drug pressure solely through provision
of SP+AS through government health facilities could
have been undermined. Firstly, in Tanzania the availabil-
ity of drugs is unregulated and varieties of anti-malarial
drugs were widely available in shops and kiosks for self-
medication during the time of this study [36]. Secondly,
the unmatched half-life of 5-10 days for the SP and 45
minutes for the AS leaves little chance for two compo-
nent drugs to work synergistically as a combination.
Consequently, any new infection acquired after AS is
cleared in the blood will likely be exposed to SP mono-
therapy providing opportunity for SP selection. Thirdly,
access to treatment was imperfect, only a proportion of
infections were treated as a result of high proportions of
untreated asymptomatic infections in this area of high
and stable malaria transmission. In the present study,
the results suggests on average 20% of healthy looking
individuals were infected with P. falciparum malaria
without expressing clinical symptoms of the disease in
Rufiji (see Table 2). This provides a very significant
reservoir of parasite populations that are not exposed to
chemotherapy [37,38]. The effect of the reservoir is that,
it provides refugia for parasites which are untreated
which compete with those exposed to ACT. Fourthly, by
the time ACT begun in Rufiji in late 2002, the dhfr tri-
ple mutant allele frequency had risen to approximately
63% compromising the possibility of mutual protection
of the component drugs in the ACT, the SP and AS.
Lastly, While National treatment policy change was
found to have a significant major effect on the frequency
of resistance alleles, the switch to ACT was applied in
one district only, and genetic exchange with surround-
ing areas which were still subject to selection by SP
monotherapy may have contributed to the dilution of
the effects of the intervention. This suggestion is sup-
ported by studies using dhfr flanking micosatellite [15]
indicating that once established resistant dhfr alleles are
highly mobile and this observation was confirmed using
similar microsatellite markers in the present study.
Alleles with intermediate resistance, double dhfr
mutant N51I+S108N and C59R+S108N did not seem to
respond to the strong selection pressure exerted by
intensified SP use in Kilombero-Ulanga nor to the
apparently reduced SP pressure by the use of ACT in
Rufiji, presenting with a constant frequency of 10%
throughout in both populations. Identification of muta-
tion at codon 164 of dhfr is a matter of great concern.
This novel resistant allele occurred as a minority mix-
ture in majority sensitive dhfr allele and in only a single
isolate in this study, suggesting that this highly resistant
dhfr genotype allele is beginning to appear but presently,
it is still very rare. In the previous study conducted on
the same area, around 7,000 P. falciparum-positive iso-
lates from both symptomatic and asymptomatic patients
were genotyped but none contained the mutant I164L
dhfr mutation. These findings corroborate recent similar
findings in different malaria endemic areas of east
Africa, Muheza-Tanzania [10], Uganda [11,14], Malawi
[12], and Kenya [13], which reported the I164L muta-
tion at a low frequency, and warn of increasing appear-
ance of this highly resistant P. falciparum in Africa.
Most encouraging perhaps is the fact that, currently
most of East African countries have already replaced SP
with artemisinin-based combination therapies (ACT) as
first-line anti-malarial treatment in their respective
national guidelines. This will markedly reduce SP usage,
which is the key determinant of its selection strength
hence limiting either further selection of I164L mutation
or establishment of its dispersal mechanism in the
population.
Assessment of the evolutionary origin of the resistant
dhfr alleles associated with pyrimethamine resistance in
P. falciparum isolates from an area of high malaria
transmission in two districts of south eastern part of
Tanzania has confirmed some previous findings, but
also generated new observations which are important
for understanding the evolution of resistance at dhfr in
African populations. The study detected high genetic
diversity in the sensitive dhfr allele supporting the view
that this is the ancestral form of dhfr [15,16]. This find-
ing is consistent with previous studies elsewhere
[13,14,16-20,30]. The predominant triple mutant dhfr
flanking microsatellite haplotype observed in this study
(H90: 108 bp/176 bp/203 bp) was identical to the Asian
type haplotype reported in [16] and subsequent studies
indicated it is widespread in Africa [13,14,17-20,39,40].
The findings of this study shows that, 25% of triple
mutant dhfr flanking microsatellite haplotypes shared
similar allele length with haplotype H90: 108 bp/176 bp/
203 bp at one or two microsatellite loci, indicating that
the variation observed are possibly explained by the evo-
lution of H90: 108 bp/176 bp/203 bp through replica-
tion errors (mutation) [32] or recombination as reported
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gence. Two haplotypes (H29: 87 bp/174 bp/207 bp and
H58: 87 bp/184 bp/199 bp), had completely different
allele length at all three microsatellite loci and exhibited
variation by 1 or 10 repeats compared to haplotype
H90: 108 bp/176 bp/203 bp, and in this case it suggests
they have arisen independently. Both haplotypes were
carrying an allele which is characteristically associated
with the dhfr double mutant at the closest microsatellite
(-0.3 Kb) loci, and this indicates that these haplotypes
may have arisen through recombination between dhfr
double mutant and dhfr triple mutant flanking
sequences after the unique dhfr haplotype H90: 108 bp/
176 bp/203 bp had undergone series of replication
errors at the -4.4 Kb and -5.3 Kb loci leading to the 1
or 2 repeat variations observed at the two distant micro-
satellite loci.
Confirmation of this interpretation may require geno-
typing of these isolates at other polymorphic sequences
that are closely linked to the dhfr gene. Assessment of
the dhfr double mutant flanking microsatellite sequences
revealed intermediate levels of diversity with sequence
variation being more conserved than the sensitives but
more diverse than the triple mutant. The two dhfr dou-
ble mutant alleles (C59R+S108N and N51I+S108N),
each had four different common haplotypes indicating
that each has arisen independently at least four times,
consistent with previous reports [15-17]. A caution how-
ever, has to be taken when interpreting haplotype H51:
(87 bp/182 bp/193 bp) which was common to both
C59R+S108N and N51I+S108N dhfr double mutant
alleles. This haplotype was the most common for the
N51I+S108N dhfr double mutant allele in the present
study and is consistent with earlier findings in the Tan-
zanian parasite population [15]. It could be a result of
mutation, recombination or both, involving the two dis-
tant loci (-4.4 Kb and -5.3 Kb) of the C59R+S108N dhfr
double mutant flanking microsatellite sequences. Gener-
ally, there was a high degree of sharing of both allele
length at different microsatellite loci among the dhfr
double and triple mutant alleles, highlighting high levels
of recombination and errors of replication associated
with extreme malaria transmission pattern of the study
area. The high level of recombination detected in our
study is consistent with recent finding in Kilifi Kenya
[20], likely reflecting high malaria transmission in the
eastern African zone.
Taken together, data from this study show that all 184
dhfr triple mutant isolates typed (perhaps with 2 possi-
ble exceptions) are related to the Asian ancestral type
previously described in [15] and later found to be dis-
persed widely in Africa [13,14,39,40]. A study in Wes-
tern Kenya has also found additional dhfr triple mutant
novel haplotypes suggesting multiple origin of the dhfr
triple mutant allele [13]. Further studies may be neces-
sary to explore the possibility of replication of Kenyan
findings. The findings of the present study however, is
very similar to reports of recent studies in Uganda [14],
Kenya [20] and that of Maiga and co-workers involving
samples from 11 sub-Saharan African countries with dif-
ferent levels of malaria transmission [19]. All these stu-
dies identified a common evolutionary history of the
dhfr triple mutant allele most likely indicating that this
unique lineage is responsible for antifolate resistance
throughout African region.
Theory suggests SP drug pressure is the driving force
behind evolution of its resistance. Positive selective pres-
sure act to increase the frequency of favoured allele
meanwhile creating association with the sequences
immediately flanking the gene. Initially there is general-
ized association but as frequency of the favoured allele
increases recombination breaks down the more distant
associations retaining only associations of the allele with
sequences immediately flanking it, the hitchhiker
[41,42]. Ultimately, the signature of selection is a pattern
of reduced gene diversity or expected heterozygosity, He
and the loss of diversity is described as selective sweep.
In the present study, the progression of triple mutant
dhfr allele frequency decreased from 11% higher in
Rufiji in 2002 to 1% lower in 2006 relative to Kilo-
mbero-Ulanga, clearly indicating reduction of SP drug
pressure by the ACT application in Rufiji. Comparison
of heterozygosity (He) values for the triple mutant dhfr
allele (C59R+N51I+S108N) after four years of SP+AS
implementation in Rufiji and four years of SP monother-
apy in Kilombero-Ulanga revealed a clear signature of
SP selection in Kilombero-Ulanga and a recovery of loss
of gene diversity in Rufiji. The diversity values dropped
from 0.65 to 0.23 in Kilombero-Ulanga population
between 2001/02 and 2006 while in Rufiji the diversity
around the allele recovered from 0.34 to 0.55 between
2001/02 and 2006 indicating that, the ACT attributable
reduction of SP selection pressure allowed the recovery
of gene diversity values through recombination (Figures
5 and 6). The observed significant reduction of gene
diversity in Kilombero-Ulanga where SP selection was
taking place since 2001 is consistent with previous
reports in parasites from south east Africa showing sig-
nificant loss of diversity across a region of 70 kb around
the triple mutant dhfr allele as an evidence of a selective
sweep attributable to selection through widespread use
of SP for the treatment of malaria [17].
Finally, like most of preceding studies, the present
study has also shown that pyrimethamine resistance is
driven by the expansion of the unique Asian triple
mutant dhfr allele lineage and recombination and errors
of replication were largely responsible for the erosion of
this lineage. This, therefore, emphasizes the role of gene
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earlier [15,17] calling for continental policies to control
the drug resistant malaria.
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